Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients

Table 3 Immunosuppressive regimens 12 mo after conversion to everolimus

Immunosuppressor regimen	n (%)	95%CI
Overall study population	n = 1471
EVL + tacrolimus + MMF ± corticosteroids	11 (7.5%)	3.2-11.7
EVL + CsA + MMF ± corticosteroids	7 (4.8%)	1.3-8.2
EVL + tacrolimus ± corticosteroids	11 (7.5%)	3.2-11.7
EVL + CsA ± corticosteroids	67 (45.6%)	37.5-53.6
Total with CNIs	96 (65.3%)	57.6-73.0
EVL + MMF ± corticosteroids	44 (29.9%)	22.5-37.3
EVL + corticosteroids	7 (4.8%)	1.3-8.2
Total without CNIs	51 (34.7%)	27.0-42.4
Patients converted due to nephrotoxicity	n = 66
EVL + tacrolimus + MMF ± corticosteroids	3 (4.5%)	0.1-9.6
EVL + CsA + MMF ± corticosteroids	5 (7.6%)	1.2-14.0
EVL + tacrolimus ± corticosteroids	3 (4.5%)	0.1-9.6
EVL + CsA ± corticosteroids	23 (34.9%)	23.4-46.3
Total with CNIs	34 (51.5%)	39.5-63.6
EVL + MMF ± corticosteroids	27 (40.9%)	29.0-52.8
EVL + corticosteroids	5 (7.6%)	1.2-14.0
Total without CNIs	32 (48.5%)	36.4-60.5

¹The missing values correspond to other combinations or to values not contained in the database. EVL: Everolimus; MMF: Mycophenolate mofetil; CsA: Cyclosporine; CNIs: Calcineurin inhibitors.